Functional CD8+ T cells infiltrate into nonsmall cell lung carcinoma
- 22 August 2006
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 56 (5) , 587-600
Abstract
Infiltration of CD3+CD8+ cytotoxic T cells was analyzed by multiparameter confocal laser microscopy in a panel of 16 randomly selected stage I nonsmall cell lung carcinomas. T-cell infiltration was observed in the stroma (range 57-,093 T cells/mm2) but also in the tumor epithelium (range 21-92 T cells/mm2) and showed wide variation between individual tumors. Interestingly, a significantly higher percentage of CD3+CD8+ T cells was detected in the tumor epithelium compared to the stroma illustrating that cytotoxic T cells may preferentially migrate into tumor epithelium. Aberrant HLA class I antigen expression was observed in 69% of the nonsmall-cell lung carcinoma (NSCLC) tumors. One tumor of a squamous cell lung carcinoma patient with the highest number of tumor infiltrating CD3+ and CD3+CD8+ cells was studied in detail and the majority (90%) of these cells were shown to be functionally activated granzyme B-positive cytotoxic T cells. DNA oligotyping of a lung carcinoma cell line established from this tumor revealed loss of one HLA haplotype corresponding with a translocation involving chromosome 6, as observed by COBRA-FISH. HLA class I-restricted tumor specific T cells could be isolated from PBMC. One further characterized cytotoxic CD8+ T cell clone, that released TNF-α, IFN-γ, and granzyme B upon co-incubation with the autologous tumor cells, was shown to be restricted by the remaining HLA-A11 allele, which was also shown to be expressed in the tumor tissue. Our data indicate that, despite HLA-haplotype loss a vigorous antitumor immune response mediated by CD8+ T-cells can be present in NSCLC offering possibilities for specific immunotherapy.Keywords
This publication has 44 references indexed in Scilit:
- Distinct patterns of genetic alterations in adenocarcinoma and squamous cell carcinoma of the lungEuropean Journal of Cancer, 2004
- Infiltrating immune cells, but not tumour cells, express FasL in non‐small cell lung cancer: No association with prognosis identified in 3‐year follow‐upInternational Journal of Cancer, 2002
- Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?Blood, 2002
- Alterations of Fas (APO-1/CD 95) gene and its relationship with p53 in non small cell lung cancerOncogene, 2001
- Tumor-Specific Cytotoxic T Lymphocyte Responses against Chondrosarcoma with HLA Haplotype Loss Restricted by the Remaining HLA Class I AlleleBiochemical and Biophysical Research Communications, 2001
- Isolation of broadly reactive, tumor-specific, HLA class-I restricted CTL from blood lymphocytes of a breast cancer patientHuman Immunology, 1999
- Review Article The immunology and immunotherapy of breast cancer: an updateInternational Journal of Immunopharmacology, 1999
- Implications for immunosurveillance of altered HLA class I phenotypes in human tumoursImmunology Today, 1997
- Biotinylated DRB sequence-specific oligonucleotides Comparison to serologic HLA-DR typing of organ donors in eurotransplantHuman Immunology, 1993
- Neu-Protein Overexpression in Breast CancerNew England Journal of Medicine, 1988